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ELIZABETH ALONSO, Ph.D., is an assistant scientist 
at the Center for Family Studies (CFS) at the University of 
Miami. Since 2004, she has worked as a coordinator and 
trainer in clinical trials with substance-using populations 
and is currently the director of quality assurance at the 
CFS. She provides consultation, training, and oversight 
of monitoring activities on numerous studies. 
KEN BACHRACH, Ph.D., is a licensed psychologist 
and the clinical director of Tarzana Treatment Centers 
(TTC), one of the largest providers of substance abuse 
and integrated behavioral health services to adults and 
youth in Southern California. He has over 25 years of 
experience in the treatment of chemically dependent 
individuals and those with co-occurring psychological 
disorders. He regularly trains substance abuse and mental 
health professionals in this area and coordinates TTC’s 
activities in NIDA’s Clinical Trials Network.
SAMUEL A. BALL, Ph.D., is a professor at Yale Univer-
sity School of Medicine in the Department of Psychiatry, 
where he also serves as the director of career development. 
He is also the director of research for The APT Foundation 
and for the NIDA-funded Resident/Intern Substance 
Use Research Education (REINSURE) and Building 
Interdisciplinary Research Careers in Women’s Health 
(BIRCWH) training programs at Yale. Dr. Ball’s major 
research interest involves the evaluation of personality 
dimensions and disorders as important constructs for 
predicting treatment outcomes and developing interven-
tions for substance-dependent patients.
 
KATHY BURLEW, Ph.D., is a professor of psychology 
at the University of Cincinnati and a member of the State 
Board of Psychology in Columbus, Ohio. Dr. Burlew is 
a former editor of the Journal of Black Psychology. Her 
publications include four books and several articles on 
substance abuse treatment and prevention. In 2007, she 
received the University Excellence in Mentoring Award 
and the Distinguished Teaching Award from the Uni-
versity of Cincinnati. 
IBIS S. CARRIÓN, Psy.D., is a clinical consultant and 
the NIDA liaison coordinator of the Caribbean Basin & 
Hispanic Addiction Technology Transfer Center in the 
Institute of Research, Education and Services in Addic-
tion at the Universidad Central del Caribe School of 
Medicine in Bayamón, Puerto Rico. Dr. Carrión has 
over 13 years of experience in the substance abuse field, 
is a licensed psychologist in Puerto Rico, and is a member 
of the American Psychological Association. 
THOMAS J. GOULD, Ph.D., is an associate profes-
sor of psychology at Temple University and head of the 
Neurobiological Investigations of Learning & Addiction 
(NILA) lab. He is also a member of the Temple Uni-
versity Neuroscience Program and an investigator and 
member of the Transdisciplinary Tobacco Use Research 
Center at the University of Pennsylvania. Dr. Gould is 
the author of more than 70 scholarly manuscripts. His 
current research interest is in the neurobiology of learn-
ing and memory, with a specific focus on identifying the 
cellular and molecular events that underlie the effects of 
nicotine and ethanol on cognition. This research also 
examines genetic factors that may contribute to the effects 
of nicotine on cognition.
CRAIG HENDERSON, Ph.D., is an assistant professor 
of psychology at Sam Houston State University. His 
research focuses on family psychology and addictive 
behaviors, particularly the treatment of adolescent sub-
stance abuse. The goal of his research is to strengthen 
family relationships of at-risk youth and to improve 
services for adolescents with substance abuse and associ-
ated problems. He also specializes in the application of 
advanced longitudinal statistical models to adolescent 
drug abuse research.
CANDACE C. HODGKINS, Ph.D., is a senior vice 
president of research for Gateway Community Services 
(GCS). She has more than 23 years of experience in the 
assessment and treatment of mental health and addiction 
disorders. She has been the principal investigator for 
eight federally funded grants for the Center for Substance 
Abuse Treatment of the Substance Abuse and Mental 
Health Services Administration and currently is GCS’s 
site principal investigator for all current protocols in 
NIDA’s Clinical Trials Network. 
VIVIANA E. HORIGIAN, M.D., is a research assistant 
professor in the Department of Epidemiology and Pub-
lic Health at the University of Miami’s Miller School 
of Medicine. Dr. Horigian has more than 11 years of 
experience in the implementation of clinical trials, includ-
ing oversight of the Brief Strategic Family Therapy for 
Adolescent Drug Abuse effectiveness trial. Currently, she 
is the program director for the Florida Node of NIDA’s 
Clinical Trials Network. 
STEVE MARTINO, Ph.D., is an associate professor of 
psychiatry at the Yale University School of Medicine. He 
specializes in the treatment of addictive disorders and of 
patients diagnosed with co-occurring psychiatric problems 
and has specific interests in motivational interviewing 
and cognitive-behavioral therapy. He also develops and 
investigates strategies for training community program 
clinicians in empirically supported treatments. Dr. Mar-
tino is the training director of the New England Node of 
NIDA’s Clinical Trials Network (CTN) and chair of the 
CTN Research Utilization Committee. In addition, Dr. 
Martino is the education director for the Yale Substance 
Abuse Treatment Psychotherapy Development Center 
and a member of the Motivational Interviewing Network 
of Trainers.
MICHAEL MILLER, Ph.D., has served The Village 
South, a substance abuse treatment facility in Miami, 
Florida, for the past 20 years in a variety of capacities. 
He directed two demonstration projects for the Center 
for Substance Abuse Treatment and was the site principal 
investigator for the Marijuana Treatment Project and two 
CTN clinical trials: Women and Trauma and Brief Stra-
tegic Family Therapy. He also trains community agencies 
in Motivational Interviewing Assessment: Supervisory 
Tools for Enhancing Proficiency (MIA:STEP). 
MARGARET MROZIEWICZ, M.Sc., worked with Dr. 
Rachel Tyndale in the Department of Pharmacology and 
Toxicology at the University of Toronto as a graduate 
student. She studied the effect of genetic variation in 
nicotine metabolism on smoking cessation with nicotine 
patch therapy.
MICHAEL S. ROBBINS, Ph.D., is a scientist at the 
Oregon Research Institute and director of research at 
Functional Family Therapy, LLC. He has extensive experi-
ence conducting research on family therapy for adolescents 
with behavior problems. Dr. Robbins—a former research 
associate professor at the University of Miami’s Miller 
School of Medicine—serves as the master trainer for 
Brief Strategic Family Therapy, overseeing the training 
of hundreds of therapists nationally and internationally. 
He has published extensively in the areas of process and 
outcome research in adolescent drug abuse treatment.
ERIC SCHINDLER, Ph.D., is the chief executive officer 
of Child & Family Resources, Inc., an Arizona com-
munity nonprofit organization dedicated to building 
strong families, preventing child abuse, and promoting 
early childhood education. He coauthored the article on 
Brief Strategic Family Therapy while he was the senior 
clinical administrator at La Frontera Center, a community 
behavioral health care organization providing integrated 
mental health and substance abuse treatment and preven-
tion services. He was the clinical treatment program prin-
cipal investigator for NIDA CTN protocols at that site.
JODY L. SINDELAR, Ph.D., is a professor and chair 
of the Division of Health Policy and Administration, 
Yale School of Public Health, and has an appointment 
at the Institution for Social and Policy Studies at Yale. 
She is also a research associate at the National Bureau of 
Economic Research in Cambridge, Massachusetts. Dr. 
Sindelar is immediate past president of the American 
Society of Health Economists. Her expertise is in the 
economics of substance abuse, including cost-effectiveness 
of treatments, behavioral economics, policy evaluations, 
and social costs. She has been principal investigator on 
a number of large National Institutes of Health grants. 
Her research has been published in economics, addiction, 
and policy journals, and she serves on several advisory 
and editorial boards.  & panel reSponDentS
JOSÉ SZAPOCZNIK, Ph.D., is a professor and chair 
of the Department of Epidemiology and Public Health, 
associate dean for community development, and direc-
tor of the Center for Family Studies at the University 
of Miami’s Miller School of Medicine. The recipient of 
numerous NIH research grants and author of many schol-
arly publications, he has been appointed to the national 
advisory councils for NIDA, the National Institute of 
Mental Health, the NIH AIDS Program Advisory Com-
mittee, and the Center for Substance Abuse Prevention.
RACHEL F. TYNDALE, Ph.D., is the Canada Research 
Chair in Pharmacogenetics and a professor in the depart-
ments of Psychiatry and of Pharmacology and Toxicology 
at the University of Toronto. She is also the pharmaco-
genetics section head at the Centre for Addiction and 
Mental Health in Toronto and vice-chair of the NIH 
Pharmacogenomics Research Network. Dr. Tyndale’s 
research focuses on pharmacogenetic variation in drug-
metabolizing enzymes and their targets in the brain and the 
resulting impact on substance dependence and treatment, 
in particular smoking. Her team also studies the regulation 
and expression of these enzymes in the brain and their role 
in drug response and neurotoxicity. Dr. Tyndale is on a 
number of editorial boards and is an associate editor for 
Clinical Pharmacology & Therapeutics. She has published 
more than 150 papers and has 10 active grants. 
 
NANCY VanDeMARK, Ph.D., has worked as an admin-
istrator, clinician, and researcher in the substance abuse 
field since 1982. She formerly worked for Arapahoe 
House, a substance abuse treatment provider in Colo-
rado, and is currently a consultant assisting state and local 
agencies with program development, implementation, 
and evaluation. 
GREG BRIGHAM, Ph.D., is chief research officer 
at Maryhaven, a substance abuse treatment facility 
in Columbus, Ohio, and a research scientist at the 
University of Cincinnati. Dr. Brigham has specialized 
in addiction treatment and prevention since 1982. 
He has developed and implemented a wide range of 
behavioral and medication-assisted treatment pro-
grams. He is active in local, State, and national efforts 
for the adoption of evidence-based practices and has 
participated in the development and implementation of 
numerous clinical trials of community-based substance 
abuse treatments. 
CARRIE DODRILL, Ph.D., is an assistant professor and 
staff psychologist at the Michael E. Debakey Veterans 
Affairs Medical Center at Baylor College of Medicine. 
She also is a member of the Motivational Interviewing 
Network of Trainers. Dr. Dodrill’s experience includes 
roles in several randomized controlled trials funded by 
the National Institutes of Health, the Centers for Disease 
Control and Prevention, and the Health Resources and 
Services Administration. She is currently involved in 
studies to reduce environmental tobacco smoke in the 
homes of infants who received neonatal intensive care, 
to use expressive writing as an intervention for depressed 
clients court-referred for alcohol and drug treatment, and 
to increase management of opioid addiction by using 
buprenorphine in primary care.
VITKA EISEN, Ed.D., M.S.W., is chief executive officer 
for Walden House, Inc., in San Francisco, one of the 
largest providers of behavioral health care to poor and 
uninsured Californians. She oversees Walden House’s 
network of substance abuse and mental health treatment, 
re-entry, and prevention services throughout California 
for incarcerated men and women, ex-offenders, and other 
substance abusers and their families in the community. 
Dr. Eisen has served on the faculty of San Francisco State 
University’s School of Social Work and Porterville Com-
munity College. She has over 20 years of experience in 
the human services field and a lifelong commitment to 
supporting people struggling with addiction and incar-
ceration.
RON JACKSON, M.S.W., is the executive director 
of Evergreen Treatment Services (ETS), a private non-
profit organization in Seattle, Washington, that pro-
vides outpatient opioid treatment to more than 1,500 
patients in clinics in Seattle and Olympia. Mr. Jackson 
has investigated various types of interventions for indi-
viduals dependent on opiates, cocaine, and marijuana. 
He is currently a co-principal investigator for the Pacific 
Northwest Node of NIDA’s Clinical Trials Network and 
is an affiliate professor at the University of Washington’s 
School of Social Work.
MICHAEL LEVY, Ph.D., is the director of clinical 
treatment services at CAB Health & Recovery Services, 
an organization that offers a full continuum of care for 
clients with substance use disorders. Dr. Levy has writ-
ten numerous articles and book chapters and has given 
many workshops that focus on working with clients with 
substance use disorders and those with co-occurring dis-
orders. In 2007 he published the book, Take Control of 
Your Drinking … And You May Not Need to Quit.
MICHAEL S. SHOPSHIRE, Ph.D., is quality assurance 
and regulatory affairs coordinator for the California-
Arizona (CA-AZ) Node of the NIDA Clinical Trials 
Network at the University of California, San Francisco. 
He is co-author of Anger Management for Substance Abuse 
and Mental Health Clients: A Cognitive-Behavioral Therapy 
Manual, which has been widely disseminated by the Cen-
ter for Substance Abuse Treatment. Dr. Shopshire actively 
works to disseminate NIDA/SAMHSA Blending Initiative 
products to community treatment programs affiliated 
with the CA-AZ Node, and he is particularly interested 
in evaluating and disseminating evidence-based substance 
abuse treatments for racial and ethnic minorities.
JOHN WANNER, M.A., L.C.A.D.C., is a counselor 
at Father Martin’s Ashley, Inc., an alcohol and drug 
treatment facility near Havre de Grace, Maryland. He 
also teaches courses in addiction counseling at the Com-
munity College of Baltimore County. Mr. Wanner 
has 15 years of counseling experience in inpatient and 
outpatient settings, addressing all aspects of patients’ 
substance abuse problems by using a combination of 
psychodynamic and cognitive-behavioral therapy. He has 
established a program tailored to the addiction problems 
of young adults.
JANET WOOD, M.B.A., M.Ed., is director of the Divi-
sion of Behavioral Health within the Colorado Depart-
ment of Human Services. Ms. Wood serves as both the 
single-State authority for substance abuse and the mental 
health commissioner for Colorado. She was a former 
presidential appointee to the White House Advisory 
Commission on Drug-Free Communities, served for 3 
years as a member of the National Advisory Council on 
Drug Abuse, and serves as vice-chair for treatment on the 
Colorado Attorney General’s State Methamphetamine 
Task Force. She has 30 years of experience in human 
services management, 20 of which she served in State 
Government.
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